LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China
September 28, 2025 19:30 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE,…
The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)
Cardiovascular disease (CVD) kills nearly 18 million people each year, more than…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Opterion Health AG submits Clinical Trial Application for First-in-Human Study of OPT101 in Patients with Advanced Chronic Kidney Disease
MUTTENZ, Switzerland, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a…
Fangzhou Unveils XingShi LLM to Advance AI-Driven Chronic Disease Management
SHANGHAI, Sept. 14, 2025 (GLOBE NEWSWIRE) -- At its 10th H2H Healthcare…
Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar”…
Psoriatic Disease To Take Center Stage at the UN General Assembly: IFPA Calls for Greater Recognition of Psoriatic Disease During UN High-Level Meetings
STOCKHOLM, Sept. 11, 2025 /PRNewswire/ -- The International Federation of Psoriasis Associations…
XingImaging in partnership with SynuSight was awarded a grant from The Michael J. Fox Foundation to support development of the -synuclein PET tracer 18F-FD4 for Parkinson’s disease
NEW HAVEN, Conn., Sept. 10, 2025 /PRNewswire/ -- XingImaging in partnership with…
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to…
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK(lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimers Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and…
